Technology

Pipeline Overview

Pipeline

Pipeline
(API)
Indication
2022
2023
2024
2025
PAT101
(Urate oxidase)
Tophaceous Gout
Non-Clinical Trial
Phase I Clinical Trial
(South Korea)
PAT102
(Arginine decarboxylase)
Cancer
(Pancreatic, Breast, Lung)
R&D
Non-Clinical Trial
Phase I Clinical Trial
PAT103
(Arginine deiminase)
Cancer
(Lung, Liver)
R&D
Non-Clinical Trial
Phase I Clinical Trial
PAT201
(GLP-1 variant)
Obesity
R&D
PAT202
(Multiple Target Peptide Variant)
Obesity
R&D
Non-Clinical Trial
Phase I Clinical Trial
PAT203
(Antibacterial peptide)
Sepsis
R&D
PAT204
(Anticancer peptide)
TBD
R&D
Pipeline
(API)
Indication
2022
2023
2024
2025
PAT101
(Urate oxidase)
Tophaceous Gout
Non-Clinical Trial
Phase I Clinical Trial
(South Korea)
PAT102
(Arginine decarboxylase)
Cancer
(Pancreatic, Breast, Lung)
R&D
Non-Clinical Trial
Phase I Clinical Trial
Pipeline
(API)
Indication
2022
2023
2024
2025
PAT103
(Arginine deiminase)
Cancer
(Lung, Liver)
R&D
Non-Clinical Trial
Phase I Clinical Trial
PAT201
(GLP-1 variant)
Obesity
R&D
Pipeline
(API)
Indication
2022
2023
2024
2025
PAT202
(Multiple Target Peptide Variant)
Obesity
R&D
Non-Clinical Trial
Phase I Clinical Trial
PAT203
(Antibacterial peptide)
Sepsis
R&D
Pipeline
(API)
Indication
2022
2023
2024
2025
PAT204
(Anticancer peptide)
TBD
R&D

EN